pc:syn5v

Syneron Bio

Syneron Bio is a biotechnology company focused on the discovery and development of next-generation macrocyclic peptide therapeutics through its proprietary Synova™ platform. The company builds a robust pipeline targeting oncology and chronic diseases and leverages drug development expertise and data science to advance therapeutic candidates.

Leadership & Board

Currently, no data available

Latest Estimated Valuation

Estimated Valuation―

Estimated Valuation―

Total Amount Raised$250M

Total Amount Raised$250M

Total Funding Rounds2

Total Funding Rounds2

Latest Funding Amount$150M

Latest Funding Amount$150M

Latest Funding RoundSeries B

Latest Funding RoundSeries B

Post-Money Valuation―

Post-Money Valuation―

Funding Round

Apr 03, 2026

Series B

$150.00M

―

Dec 19, 2025

Series A

$100.00M

―

Investors

Series A

Series A

Series A

Series A

AZ-CICC Healthcare Investment Fund

Series A

Pfizer Biotech Development Investment Fund

Series A

Sinovation Capital

Series A

Series A

Related News and Analysis

Syneron Bio Raises $150 Million in Series B to Advance AI-Driven Peptide Drug Platform

Syneron Bio Raises $150 Million in Series B to Advance AI-Driven Peptide Drug Platform

New updates have been reported about Syneron Bio. Syneron Bio has closed a $150 million Series B financing...

7d ago

Ro Adds Lilly’s Oral GLP-1 Foundayo to Expand Obesity Treatment Platform

Ro Adds Lilly’s Oral GLP-1 Foundayo to Expand Obesity Treatment Platform

New updates have been reported about Ro. Ro has added Eli Lilly’s new oral GLP-1 drug Foundayo (orforglipron)...

19h ago

AllRock Bio Begins Phase 2a ROCSTAR Trial of Lead Pan-ROCK Inhibitor in Pulmonary Hypertension

AllRock Bio Begins Phase 2a ROCSTAR Trial of Lead Pan-ROCK Inhibitor in Pulmonary Hypertension

New updates have been reported about AllRock Bio. AllRock Bio, Inc. has initiated patient dosing in its Phase...

20h ago

Trogenix Preclinical Breakthrough in Glioblastoma Paves Way to First-in-Human Trial

Trogenix Preclinical Breakthrough in Glioblastoma Paves Way to First-in-Human Trial

New updates have been reported about Trogenix. Trogenix has published preclinical data in Nature showing complete tumor clearance...

21h ago

Bedrock Data Recognized Among Fast-Growing Midsize Cybersecurity Firms

Bedrock Data Recognized Among Fast-Growing Midsize Cybersecurity Firms

According to a recent LinkedIn post from Bedrock Data, the company has been included in IT-Harvest’s 2026 Cyber...

1d ago

Cornerstone Robotics Showcases Sentire Surgical System at CMEF Shanghai

Cornerstone Robotics Showcases Sentire Surgical System at CMEF Shanghai

A LinkedIn post from Cornerstone Robotics highlights the company’s participation in the 93rd China International Medical Equipment Fair...

1d ago

ClickHouse Targets Real-Time AI Data Workloads With Expanded Conference Presence

ClickHouse Targets Real-Time AI Data Workloads With Expanded Conference Presence

According to a recent LinkedIn post from ClickHouse, the company is planning a broad presence at the AI...

1d ago

Cohesity Highlights Cyber Resilience Focus, Nutanix Partnership and Customer Recognition

Cohesity Highlights Cyber Resilience Focus, Nutanix Partnership and Customer Recognition

According to a recent LinkedIn post from Cohesity, the company is emphasizing the limitations of largely manual and...

1d ago

Cohesity Positions Data Recovery as Key Risk Mitigation for AI-Driven Security

Cohesity Positions Data Recovery as Key Risk Mitigation for AI-Driven Security

A LinkedIn post from Cohesity highlights the growing security risks tied to agentic artificial intelligence in enterprise environments....

1d ago

AdvantageClubai Highlights Filipino Day of Valor and Workplace Culture Focus

AdvantageClubai Highlights Filipino Day of Valor and Workplace Culture Focus

According to a recent LinkedIn post from AdvantageClubai, the company is marking the Philippines’ Araw ng Kagitingan (Day...

1d ago